Research Topics
| Gerald V NaccarelliSummaryAffiliation: Pennsylvania State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillationGerald V Naccarelli
Division of Cardiology and the Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, Hershey, PA 17033, USA
J Interv Card Electrophysiol 9:215-22. 2003..Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation...- Atrial fibrillation in heart failure: prognostic significance and managementGerald V Naccarelli
Division of Cardiology and the Penn State Cardiovascular Center, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
J Cardiovasc Electrophysiol 14:S281-6. 2003..The article presents an overview of atrial fibrillation in patients with heart failure and reviews the prevalence, prognostic significance, and efficacy of various antiarrhythmic agents for the conversion and maintenance of sinus rhythm... - Implantable cardioverter-defibrillators: expanding indicationsGerald V Naccarelli
Division of Cardiology and Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
Curr Opin Cardiol 19:317-22. 2004..This article reviews multiple secondary and primary prevention trials that have expanded the indications for implantable cardioverter-defibrillators (ICDs)... - Does it make sense to train plumbers as electricians?Gerald V Naccarelli
Division of Cardiology and the Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
J Am Coll Cardiol 44:1358-60. 2004..In this paper, a pathway is presented that would combine training in HF/transplantation and cardiac implantable electrical devices... - New antiarrhythmic treatment of atrial fibrillationGerald V Naccarelli
Penn State University Heart and Vascular Institute, The Electrophysiology Program, Penn State University College of Medicine, The Milton S Hershey Medical Center, 500 University Dr, Room H 1 511, Hershey, PA 17033, USA
Expert Rev Cardiovasc Ther 5:707-14. 2007..Future studies will clarify the role of these drugs in treating AF... - Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunctionGerald V Naccarelli
Division of Cardiology, Cardiovascular Center, Penn State University College of Medicine, The Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
Clin Cardiol 28:165-73. 2005..Recent trials of implantable cardioverter-defibrillators added to pharmacologic therapy, especially beta blockers, have shown a further reduction in arrhythmic deaths in these patients... - Antiadrenergic therapy in the control of atrial fibrillationGerald V Naccarelli
Division of Cardiology, Penn State University, College of Medicine, The Milton S Hershey Medical Center, Hershey, PA
J Cardiovasc Pharmacol Ther 10:S33-43. 2005..Carvedilol is effective, alone or in combination, with digoxin in such heart failure patients with AF, and has been shown to reduce mortality risk in patients with chronic heart failure during prolonged therapy... - Does carvedilol have antiarrhythmic properties?Gerald V Naccarelli
Division of Cardiology, Penn State University College of Medicine, Hershey, PA 17033, USA
Nat Clin Pract Cardiovasc Med 2:338-9. 2005 - Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devicesGerald V Naccarelli
Division of Cardiology, Pennsylvania State University, College of Medicine, The Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
Clin Cardiol 28:I51-7. 2005..Implanted devices must be followed up appropriately, with periodic interrogation and program adjustment to reduce the risk for pacing-induced desynchronization and to optimize hemodynamic benefit... 
Angiotensin II receptor blockers in the prevention of complications from atrial fibrillationGerald V Naccarelli
Penn State Heart and Vascular Institute, Hershey, Pennsylvania 17033 3907, USA
Vasc Health Risk Manag 5:783-91. 2009..Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF...
Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future?Gerald V Naccarelli
Penn State University Heart and Vascular Institute, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
J Cardiovasc Pharmacol 52:203-9. 2008....- Vernakalant: pharmacology electrophysiology, safety and efficacyGerald V Naccarelli
Division of Cardiology, Penn State University Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA 17033, USA
Drugs Today (Barc) 44:325-9. 2008..In addition, preliminary data suggest that it could also suppress recurrences when used orally. This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant... - Advances in the treatment of atrial fibrillation: the future is nowGerald V Naccarelli
Division of Cardiology and Cardiovascular Center, Pennsylvania State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA 17033, USA
J Interv Card Electrophysiol 10:77-8. 2004 - Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillationGerald V Naccarelli
Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1 511, Hershey, PA 17033, USA
Expert Opin Investig Drugs 17:805-10. 2008..In addition, this drug has important rate-dependent sodium channel blocking properties... - Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablationGerald V Naccarelli
Hershey Medical Center, Division of Cardiology, 500 University Drive, Hershey, PA 17033, USA
Curr Cardiol Rep 4:418-25. 2002..Hybrid therapy using drugs in combination with nonpharmacologic approaches will be used more frequently in the future for refractory patients... - Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trialsGerald V Naccarelli
Division of Cardiology and the Penn State Cardiovascular Center, Penn State University College of Medicine, The Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
Am J Cardiol 91:15D-26D. 2003..In post-myocardial infarction patients, sotalol is an additional agent to consider for treatment of AF in this setting... - Intracardiac echocardiography in complex cardiac catheter ablation proceduresJavier E Banchs
Penn State Heart and Vascular Institute, Penn State University College of Medicine, 500 University Drive, H047, Hershey, PA 17033, USA
J Interv Card Electrophysiol 28:167-84. 2010.... - Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapiesGiselle A Baquero
Heart and Vascular Institute, Penn State College of Medicine, Hershey, Pennsylvania, USA
J Cardiovasc Electrophysiol 23:296-301. 2012..Dofetilide has only been approved for the treatment of atrial fibrillation. The role of dofetilide in the control of ventricular arrhythmias in patients with an ICD has not been established... - Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutterJavier E Banchs
Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, 500 University Drive, P O Box 850, Hershey, PA, 17033 0850, USA
J Interv Card Electrophysiol 23:111-5. 2008..It is not known, however, whether pharmacological conversion with dofetilide predicts maintenance of sinus rhythm. In addition, there is limited information comparing the efficacy of dofetilide in persistent versus paroxysmal AF/AFL... - Selection of drugs in pursuit of rate control strategySoraya M Samii
Division of Cardiology, Pennsylvania State Cardiovascular Center, Penn State University College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA 17033, USA
Prog Cardiovasc Dis 48:146-52. 2005..Adequate rate control can be achieved by atrioventricular nodal blocking agents both in the acute and chronic settings. In refractory patients, other methods such as atrioventricular node ablation can be used to control rate... - A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submissionGerald V Naccarelli
Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA
J Cardiovasc Pharmacol Ther 15:24S-30S. 2010..Dronedarone is a novel, multichannel blocking antiarrhythmic agent that may have some pleiotropic effects in addition to its ability to suppress and maintain sinus rhythm and control the rate during AF/AFL recurrences... - Atrial fibrillation in patients with heart failureB John Hynes
Division of Cardiology, Penn State University College of Medicine, Hershey, PA 17033, USA
Curr Opin Cardiol 18:32-8. 2003.... - Complications of biventricular pacingLuna Bhatta
Division of Cardiology, Penn State Cardiovascular Center, Pennsylvania State College of Medicine, Hershey, USA
Curr Opin Cardiol 19:31-5. 2004..This review summarizes the data derived from major clinical trials about the complications related to implantation, hardware, and programming of biventricular devices... - Rates and implications for hospitalization of patients ≥65 years of age with atrial fibrillation/flutterGerald V Naccarelli
Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, Hershey, Pennsylvania, USA
Am J Cardiol 109:543-9. 2012..Measures that lower inpatient admission rates, particularly readmission rates, may reduce the increasing cost of treating patients with AF or AFL with Medicare supplemental insurance... - Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United StatesGerald V Naccarelli
Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Penn State University, Hershey, Pennsylvania 17033, USA
Clin Cardiol 33:270-9. 2010..001) in patients with atrial fibrillation (AF) and atrial flutter (AFL)... - CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patientsGerald V Naccarelli
Penn State Heart and Vascular Institute, Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
Am J Cardiol 109:1526-33. 2012..In conclusion, CHADS(2) and CHA(2)DS(2)-VASc scores were predictive of first CV hospitalization in patients with AF or AFL and may be helpful in identifying "at-risk" patients and guiding therapy... - Post-ATHENA and beyondGerald V Naccarelli
Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA
J Interv Card Electrophysiol 31:55-60. 2011..These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect... - Paroxysmal atrioventricular block following a ventricular premature beatJavier E Banchs
Heart and Vascular Institute, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania 17033-0850, USA
J Cardiovasc Electrophysiol 18:230. 2007 - Role of intracardiac ultrasound in interventional electrophysiologyB John Hynes
Division of Cardiology and Pennsylvania State Cardiovascular Center, Pennsylvania State University, College of Medicine, Hershey 17033, USA
Curr Opin Cardiol 19:52-7. 2004..SUMMARY: A comprehensive look is provided at the history and development of this new technology along with the most recent applications of ICE in interventional electrophysiology... - Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendationsGerald V Naccarelli
Division of Cardiology, Penn State Heart and Vascular Institute, Hershey, PA 17033, USA
J Cardiovasc Pharmacol Ther 15:244-56. 2010.... - Distal balloon occlusion allows epicardial lead placement in a tortuous branch of the great cardiac veinParag Patel
Penn State Heart and Vascular Institute, Milton S Hershey Medical Center, Hershey, PA, USA
J Interv Card Electrophysiol 25:159-61. 2009..This approach can be used in navigating lead placement to branches thought to be unreachable. Techniques such as this can decrease the failure rate of CRT implants... - Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutterGerald V Naccarelli
Penn State Hershey Heart and Vascular Institute, Cardiac Electrophysiology Program, Hershey, PA, USA
Clin Med Insights Cardiol 5:103-19. 2011..In addition, the recent results of the PALLAS trial suggest that dronedarone should not be used in the long-term treatment of patients with permanent AF... - Device therapies in the post-myocardial infarction patient with left ventricular dysfunctionAlan H Kadish
Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Am J Cardiol 102:29G-37G. 2008..Further risk stratification studies of post-MI LVD patients will allow ICD therapy to be applied in a more cost-effective manner... - The Brugada syndromeGerald V Naccarelli
Division of Cardiology, Cardiovascular Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
Curr Opin Cardiol 17:19-23. 2002..Because of the poor prognosis of such patients, symptomatic patients should be treated with an implantable cardioverter-defibrillator... - Biventricular pacing in congestive heart failure: a boost toward finer livingJerry C Luck
Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033-0850, USA
Curr Opin Cardiol 17:96-101. 2002..The acute hemodynamic studies suggest that resynchronization pacing therapy may predict a positive long-term benefit for many patients with congestive heart failure... - Entrainment of ventricular tachycardia with a permanent biventricular pacemakerJerry C Luck
Department of Medicine, Section of Cardiology, Milton S Hershey Medical Center, Pennsylvania State University 17003, USA
J Interv Card Electrophysiol 7:105-11. 2002..The entrance and exit points of the loop for VT appeared to rest between the two pacing sites in the intraventricular septum. This case illustrates one of the sensing limitations of today's biventricular pacing defibrillator systems... - Increasing prevalence of atrial fibrillation and flutter in the United StatesGerald V Naccarelli
Pennsylvania State Heart and Vascular Institute, Milton S Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA
Am J Cardiol 104:1534-9. 2009..The current and projected increases in the prevalence of AF are greater than predicted by a previous sentinel study and might reflect more than the aging of the population... - Left ventricular aneurysm as a consequence of hypertrophic obstructive cardiomyopathyPatrick H McNulty
Cardiovascular Center, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
Catheter Cardiovasc Interv 55:385-8. 2002 - Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRMKatherine T Murray
Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Heart Rhythm 1:669-75. 2004..We investigated whether inhibition of endogenous angiotensin II signaling reduces the recurrence rate of atrial fibrillation (AF) in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study... - ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee toGabriel Gregoratos
Circulation 106:2145-61. 2002 - NASPE training requirements for cardiac implantable electronic devices: selection, implantation, and follow-upDavid L Hayes
North American Society of Pacing and Electrophysiology, Natick, Massachusetts 01760-2499, USA
Pacing Clin Electrophysiol 26:1556-62. 2003 - Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trialsFranco Naccarella
Cardiology Department, Day Hospital Tiarini Corticella, Azienda USL, Citta di Bologna, Cardiology University of Parma, Italy
Curr Opin Cardiol 17:6-18. 2002..Finally, according to these clinical evidences, in the last part of the review, we stress the need for a more widespread implementation of ACE-I and AII-a in treating CHF patients... - Task Force 6: training in specialized electrophysiology, cardiac pacing, and arrhythmia management: endorsed by the Heart Rhythm SocietyGerald V Naccarelli
J Am Coll Cardiol 47:904-10. 2006 - Task force 6: training in specialized electrophysiology, cardiac pacing, and arrhythmia management endorsed by the Heart Rhythm SocietyGerald V Naccarelli
J Am Coll Cardiol 51:374-80. 2008 - Can we predict antiarrhythmic efficacy or inefficacy of amiodarone or any other antiarrhythmic? What this patient needs is a doctor!Gerald V Naccarelli
J Cardiovasc Electrophysiol 15:1155-6. 2004 - Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythmMarc Cohen
Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
J Cardiovasc Electrophysiol 19:885-90. 2008..Because of the limited efficacy and adverse effects of current antiarrhythmics, new antiarrhythmic drugs need to be developed that provide safer and more effective rhythm control in AF... - A practical guide for clinicians who treat patients with amiodarone: 2007Nora Goldschlager
University of California, San Francisco, California, USA
Heart Rhythm 4:1250-9. 2007..The recommendations included herein are based on the best available data and the collective experience of the member of the writing committee... - Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice?James A Reiffel
Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA
Clin Cardiol 29:97-102. 2006..However, market research and clinical study data indicate a growing use of class III agents (mainly amiodarone) despite long-term safety and tolerability concerns, suggesting that clinical practice does not adhere to current guidelines... - Can incremental innovation of implantable cardioverter-defibrillator systems become disruptive to patient care? Moore's law gone awryGerald V Naccarelli
J Cardiovasc Electrophysiol 17:621-2. 2006 - Fast-track training of nonelectrophysiologists to implant defibrillators: is it needed?Brian Olshansky
University of Iowa School of Medicine, Iowa City, Iowa, USA
Pacing Clin Electrophysiol 29:627-31. 2006..We are particularly concerned about the disruption of training pathways in medicine and how this can affect patient care and can influence established training pathways in medicine... - ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee toGabriel Gregoratos
J Cardiovasc Electrophysiol 13:1183-99. 2002 - ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee toGabriel Gregoratos
Resource Center, American College of Cardiology Foundation, 9111 Old Georgetown Road, Bethesda, MD 20814-1699, USA
J Am Coll Cardiol 40:1703-19. 2002 - Ambulatory electrocardiographic monitoring: has mobile cardiac outpatient telemetry changed the playing field?Gerald V Naccarelli
J Cardiovasc Electrophysiol 18:248-9. 2007 - Working group 1: How to increase the output of cardiologistsKenneth Lee Baughman
J Am Coll Cardiol 44:233-7. 2004